Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;38(8):1822-1824.
doi: 10.1038/s41375-024-02285-9. Epub 2024 Jun 15.

Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients

Olga Sala-Torra  1 , Lan Beppu  1 , Qian Wu  2 , Emily Welch  3 , Erwin Berthier  3 , Jerald P Radich  1   4 , Vivian G Oehler  5   6
Affiliations

Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients

Olga Sala-Torra et al. Leukemia. 2024 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Olga Sala-Torra, no competing financial interests. Lan Beppu, no competing financial interests. Qian Wu, no competing financial interests. Emily Welch, former employment, Tasso, Inc. Erwin Berthier, employment, Tasso, Inc. Jerald P. Radich, Novartis, consulting and Cepheid, consulting. Vivian G. Oehler, Pfizer, Inc. research support and consulting; Novartis, consulting; Ascentage Pharma, consulting; Terns Pharmaceuticals, consulting.

Figures

Fig. 1
Fig. 1. Capillary dried blood sampling by Tasso-M20 and correlation of venous vs. dried capillary BCR::ABL1%.
a Overview of the Tasso-M20 device. b After log10 transformation, R is 0.99 between the two raw measures and 0.96 between the two log10 transformed measures (log10 (x + 1) vs. log10 (y + 1)). c Bland-Altman Plot showing the bias as the difference between the log10 transformed values of the venous and capillary samples (log10 (x + 1) and log10 (y + 1)). Bias = 0.06.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7. 10.1200/JCO.2015.66.2866 - DOI - PubMed
    1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. 10.1038/s41375-020-0776-2 - DOI - PMC - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Chronic Myeloid Leukemia V.2.2024.© National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [December 15, 2023].
    1. Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Di M, et al. Contemporary “real world” molecular testing and tyrosine kinase inhibitor adherence patterns among older patients with chronic myeloid leukemia in the United States. Blood. 2021;138:282.10.1182/blood-2021-151066 - DOI
    1. Rowley S, Garcia-Gonzalez P, Radich JP, Novakowski AK, Usherenko I, Babigumira JB. Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries. Cost Eff Resour Alloc. 2021;19:18. 10.1186/s12962-021-00271-x - DOI - PMC - PubMed

MeSH terms

Substances